BFTC-905 Cells

The BFTC-905 cell line is a human transitional cell carcinoma (TCC) model derived from a high-grade, papillary bladder tumor in a female patient. It was established to represent aggressive bladder cancer and has been used in cytogenetic and molecular profiling studies to understand bladder tumor biology and therapeutic vulnerabilities. BFTC-905 exhibits a highly complex and rearranged karyotype, which includes multiple chromosomal abnormalities typical of advanced bladder cancers. These include non-random alterations such as deletions of 8p, duplications of 8q, and gains in chromosomes 7 and 20, features often linked to disease progression and poor prognosis in urothelial carcinoma.

Extensive characterization using multi-color fluorescence in situ hybridization (M-FISH) has revealed numerous structural rearrangements in BFTC-905, including interchromosomal translocations and deletions affecting loci with potential relevance to tumor suppressor loss. Specifically, BFTC-905 displays a deletion of chromosome 8p21, a region frequently lost in aggressive TCC and associated with tumor suppressor genes. This cytogenetic complexity provides a valuable opportunity for dissecting gene function in the context of genomic instability, a hallmark of late-stage bladder cancers.

BFTC-905 has also been included in large-scale pharmacogenomic studies such as the Cancer Cell Line Encyclopedia (CCLE) and Genomics of Drug Sensitivity in Cancer (GDSC). These resources have confirmed the molecular fidelity of BFTC-905 to primary bladder tumors and have enabled its use in predictive modeling of anticancer drug responses. Its multi-omics profile-including gene expression, mutation status, copy number variation, and DNA methylation-makes it a powerful model for investigating bladder cancer-specific therapeutic targets and resistance mechanisms.